{"name":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","slug":"instituto-nacional-de-ciencias-medicas-y-nutricion-salvador-zubiran","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"zidovudine + lamivudine + efavirenz","genericName":"zidovudine + lamivudine + efavirenz","slug":"zidovudine-lamivudine-efavirenz","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"zidovudine+lamivudine+lopinavir/ritonavir","genericName":"zidovudine+lamivudine+lopinavir/ritonavir","slug":"zidovudine-lamivudine-lopinavir-ritonavir","indication":"HIV-1 infection","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Placebo (for Bezafibrate)","genericName":"Placebo (for Bezafibrate)","slug":"placebo-for-bezafibrate","indication":"Control arm in Phase 3 trial of Bezafibrate (fibrate for dyslipidemia/cardiovascular risk reduction)","status":"phase_3"}]}],"pipeline":[{"name":"Placebo (for Bezafibrate)","genericName":"Placebo (for Bezafibrate)","slug":"placebo-for-bezafibrate","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":["Control arm in Phase 3 trial of Bezafibrate (fibrate for dyslipidemia/cardiovascular risk reduction)"],"catalyst":""},{"name":"zidovudine + lamivudine + efavirenz","genericName":"zidovudine + lamivudine + efavirenz","slug":"zidovudine-lamivudine-efavirenz","phase":"marketed","mechanism":"This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"zidovudine+lamivudine+lopinavir/ritonavir","genericName":"zidovudine+lamivudine+lopinavir/ritonavir","slug":"zidovudine-lamivudine-lopinavir-ritonavir","phase":"marketed","mechanism":"This combination inhibits HIV replication by blocking reverse transcriptase (zidovudine and lamivudine) and protease (lopinavir/ritonavir) enzymes required for viral reproduction.","indications":["HIV-1 infection"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":1,"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}